Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (41-50 of 264) with videos related to

Pageof 27
Sort By:
Cancer Treatment Reviews|March 23, 2010
Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomyAlessandra Balduzzi, Maria Cristina Leonardi, Anna Cardillo, et al.
Clinical Breast Cancer|August 6, 2017
Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and OutcomesEmilia Montagna, Sara Pirola, Patrick Maisonneuve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2018
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5Mitch Dowsett, Ivana Sestak, Meredith M Regan, et al.
The Lancet. Oncology|June 9, 2018
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trialGunter von Minckwitz, Marco Colleoni, Hans-Christian Kolberg, et al.
Drug Safety|January 14, 2020
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC StudyHans-Christian Kolberg, Marco Colleoni, Georgia Savva Demetriou, et al.
Lancet (London, England)|September 27, 2005
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass indexMarco Colleoni, Sigui Li, Richard D Gelber, et al.
Journal of the National Cancer Institute|March 12, 2010
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?Olivia Pagani, Elzbieta Senkus, William Wood, et al.
Clinical Breast Cancer|April 9, 2014
Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugsCaterina Fumagalli, Silvia Della Pasqua, Vincenzo Bagnardi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 10, 2010
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapyLaura Gilardi, Concetta De Cicco, Marco Colleoni, et al.
Cancer|June 15, 2007
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapyMaria Teresa Sandri, Harriet Ann Johansson, Laura Zorzino, et al.
Pageof 27

Showing results (41-50 of 264) with videos related to

Sort By:
Pageof 27
Cancer Treatment Reviews|March 23, 2010
Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomyAlessandra Balduzzi, Maria Cristina Leonardi, Anna Cardillo, et al.
Clinical Breast Cancer|August 6, 2017
Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and OutcomesEmilia Montagna, Sara Pirola, Patrick Maisonneuve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2018
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5Mitch Dowsett, Ivana Sestak, Meredith M Regan, et al.
The Lancet. Oncology|June 9, 2018
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trialGunter von Minckwitz, Marco Colleoni, Hans-Christian Kolberg, et al.
Drug Safety|January 14, 2020
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC StudyHans-Christian Kolberg, Marco Colleoni, Georgia Savva Demetriou, et al.
Lancet (London, England)|September 27, 2005
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass indexMarco Colleoni, Sigui Li, Richard D Gelber, et al.
Journal of the National Cancer Institute|March 12, 2010
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?Olivia Pagani, Elzbieta Senkus, William Wood, et al.
Clinical Breast Cancer|April 9, 2014
Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugsCaterina Fumagalli, Silvia Della Pasqua, Vincenzo Bagnardi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 10, 2010
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapyLaura Gilardi, Concetta De Cicco, Marco Colleoni, et al.
Cancer|June 15, 2007
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapyMaria Teresa Sandri, Harriet Ann Johansson, Laura Zorzino, et al.
Pageof 27